Docusign Envelope ID.. 5E8567BB_3EOA48C&8EB4BBDE7113B265 COMPANY REGISTRATION NUMBER 6310215 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CONSOLIDATED FINANCIAL STATEMENTS 31 DECEMBER 2024 Charlty Number 1121258 Docusign Envelope ID.. 5EB567BB-3EOA48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2024 CONTENTS PAGE Chalrman's Stal8m8nt Trustees Annual R8POrt Independent auditor's report to the members 14 Con8olldated St8tement of financlal actlvities (incorpor8tlng iha Income and expendlture account) 17 Charity Statement ol financial activities {incorpor8ting the incom8 and expenditure account) 18 Con801idated Balance sheet 19 Charity Balance sheet 20 Consolidated Statement ol Cashlows 21 Charity Statement of Cashflows 22 Notes to the financial st8t8ments 23 Docusign Envelope10.' 5EB567B8_3EOA_48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHAIRMAN'S STATEMENT YEAR ENDED 31 DECEMBER 2024 2024 was a year of significant achievemenl for th8 charsly. we were able lo recogni88 and celebr8le the success of our research team at our first r858arch conference. The event was huge success. bringing logelhvr r8pregentatives from th8 entire ABC famlly. from researchers to volunteers, wg came logelh8r lo hear abjul the late51 developm8nls and learnings from key member9 of the team. Thanks musl go lo Oriel College in Oxford for proving a wonderful venue, such was the SUGGess. we hope to make the r8S8arch conference a biennial ev8nl. Individually we Longralulaled res&arch team members who were reclpienls of prestigious award5. Each recelving r8cognition for their broad influence in their respective fields of research. Such recognitlon is ollly made p099lble Ihrough teamwork. Once again tho close relalionshlps that exist b8hv88n tliu research tgam and charity staff were on dlsplay os they worked to complete the Iran8f8r of the DielCompLyf biobank lo Universlly of Soulhampton. The 8iobank wlll mak8 an important conlrfbulion lo ongolng development of the miONCO 1851 described by Secretary of Stale Tor Health and Social Care Wes Slreeling as 'game ch8nging', Of course, none of Ihls would be possible wilhout the support of the wid8r communlly. This ye8r fundr81S8r8 teking part in th￿ ever popular Breast Walk Ever gol lo meet key members Df our re88arch team ag they once again volunteered 10 8Ct as mar8hal8 81 various points on the course. Impr()vgrnenls madp. In Ihp w8bsile by the lundraising team resulted in a slgnificanl increase in the numbp.r of supporters taking part in events in Ihe UK and bnyond. Elsewher8, the incredible Charily AngalA team took Ihelr fundrai8ing over £1 OU,OUO a8 they hosted a fashion show In Kent ané dinner at the Army & Navy club In Pall Mall. Fin811y, 2024 was our busie81 y8ar on record for admini8lering charitable estate8. Glfls in Wlllg héve contributed towards every discov8ry our research scienlisls have made. We are grateful Ic each of those supporters who cliose leave us 8 legacy, each taking us one slep closer to our goal - a future fr88 from breast cancer. Richard B8hu Chair of Trustaes 14 /pks Docusign Envelope ID.. SEB567BB-3EOA48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) (conlinued) YEAR ENDED 31 DECEMBER 2024 The Iruslees, who are also directors for the purp05es of company law, present their report and the flnancial slalemenls of the charity for the year ended 31 December 2024. OBJECTIVES AND ACTIVITIES Agalnsl 8reast Cancer (ABC) wa5 establi8h8d lo fund unique re5e8rch into Secondary breast cancer, the main cause of brea81-cancer related deaths. The secondary spread of breast cancer, or met8818Si8, is currently an incurable condition which ran tsccur in up lo 40°A of breast cancer patient5, sometimes years after a primary di8gnosis and Ir8almenl. which claims the lives of 12,000 people eBch year in the UK. ABC raise money lo increase Ihe 8uNival rates of br8a81 canc8r pa118nls by supporting res8arch in 4 areas., 1) to develop Irealm8nls for secondary breasl cancer. ullim8tely a vaccina 21 lo develop tools for the earlier diagnosis ol secondary breast cancer 31 to understand which di8t and Ilfestyle factors impact risk of recurrence or 8pread 4> to provide 8 platfomi for cornmunicaiion to dflV8 the scienlific field forward. ABC founder and breast cancer researther Dr. Anlhony Le8lhem dis¢ov8red a difference in Ihe sugar archi1oCtur8 the glycobiology - on aggres8iv8 breast cancers compared io less inv88ive type8 of breast cancer. Publlc 88ngflt The Trustees cunfirm that Ih8y have complled wlh the duty of $8cllon 17 of the Charllles Act 2011 to have duo regard to the guldance155ued by The Charity Commission on public b8n8fl1. The charitable purpose for the charity within the meaning of thu Act 18 enBhrined ￿thIn its objectives 51aled above. The holistic approach lo our r85earch strategy exists lo bengfil the 6UU,OUO p80ple curranlly living with a diagnusi¥ of br8851 cancer in the UK and predicted lo ris& 10 1.2 million by 2030. Our research falls under three main Ihemes: Prevention. 0oleGkn'on, and Therapy. While the Thefapeutlc Antibody programme prfncipolly focusses on Therapy, our research Into Prev8nlion and Delecliori Is complemented by th8 expected 8slabli8hment of the new ABC Biobank which will b8 cIo88ly linked ICJ the ABC Discover programme. Prevention is Iocused ori ifnproving our understanding of the underlyinq biologlc81 and Immunolryical mechanisms driving th8 assoclelion between diet. lifeslyle, 8nd bre8s1 cancer metsslasis. This undersianding will bell8r Inlorm our approach lo d8veloping novtrl immunolh8r8pi8s and maximise IheSr Ih8rapeulic efficacy. Oeteclion, involves working lo idenlify glycan biomarkers that will offer novel largtsls for therapy. In parallel, we aro continuing our slra18gy of developing nov81 Herc8plin derivaliv8S through the gxploitalion of antibody engineering. As the project$ in the prevention and dglection theme develop the5￿ will feed into the therapy theme, further informing our design approach. This slr818gy aligns with our overall amblliDn lo g81 our mosl promising Ihorapeulic molecule Into GliniG81 Irials. We also 8lfll to 8volv8 the prograrnme lo unite experlmenlal immunotherapies with the longterm and on-go(ng work by ABC on understanding the impact of Dlel & lifeslyle. Where uppurtunities exist to 8cc81erale projects. Again818rea8t Cancer works In collaboratlDn wlth olher funding bodies. Results of our funded research projects a￿ published in peer-reviewed journals. Details of 811 published papers ar available from the charity website. ACHIEVEMENTS AND PERFORMANCE The Trustee5 provid8 good governance by safeguarding and promDling the organi5alions reputation and acting according lo high ethical standards. They ensure Ihat the chafily acts in a responsiblB manner in accordance with good lundraisiNg practice. Doojsign Envelope ID.. SE8567BB-3EOA48C>8EB4_8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) (eontlnued) YEAR ENDED 31 DECEMBER 2024 Agalnst Breast Cancer Research Report 2024 ABC Rejgarch Conference 19th Jun8 2024, Oriol College Oxford Ag8insl Br8ast Cancer researchers and the wider ABC communily g8lh8red for the inaugural ABC r85earch conference. Almost 60 people allenéed the COnfe￿nCe which w8 feel was a huge success. Researchers, stsff, volunteers, $cionlific advisory board members, supporters. pallenl advocates and 8arly c8r8er research students came log8lh8r to hear about the Lglest AB funded research and engage with our expert panel. Orlel provided a wonderful venue including hosting Ihe reception in the grand College H811. Delegate feedback137 respondents) was exlr8m¥ly positive. We hope lo mak8 the conference 8 biennial event w5th the next event planned for springlsummer 2026 al Ori81 College. Llnlv•rxlty of Southampton AgalnAt 8rea•t C8ncor Programme Granl In Th•rapoullG Antibodies 2018-2028 Academic Staff.. Dr Charlie Birts, ABC Lecturer in Anllbody Therapeullcs, Prof. Max Crlspin. Director of the Inslilule of Lif8 Sclences Prof. Sl8ph8n Beer5, ProfBs50r of Immunology & lrnrnunolherapy Senior %rienlisl', Dr John Butler, Posl-D()Lli)ral fellow and Lab Manager Technical Staff.. Anna-Liese Silber. Technician, Centre for Cancer lrnmunology PhD Students.. IABC proj8Ct8l Grace H8ye8- 3rd year The A8C TherapuuliL Antibody Prooramm8 al University of Soulhamplon is a 10-y8ar programm& vllh 8 main focus on developing new therapies. bul the rese8rch has significant ovvrlap 8nd 5ynergie5 across all three ABC th8m88 of research Prevention. Delecli(N) and Therapy. The Th8rappulic antibody programme alms lo omplement the ABC Discover Programme and studies on the OielCompLyf Biobank upon it's Iiansfer to Soulhalnpton. Ov•rvi•w The Uos le8m lakes a holistic approach for the A8C Programme In Th8rapeulic Antibodies and the research brD8dly fBlls under the three main Ihem8s of Prevention, Detection. and Therapy. While the Therapeutic Antibody programme principally focusses on Therapy. aclivS1ies are growing tu include Prevention and Deleclion. This complements the ABC DielCompLyf Biobank and we will be working to closely complement the n8w ABC Discover programme. Lay Summary of Progr8SS Dev?loping model8 for breast cancer spread Th8 Soulhamplon 18am have cr8818d modified breast cancercell lines with fluorescent mark8rs Its h￿.(p track tuniour spffjad in mice and ob5erv8 how cancer calls Iravel lo bones and olher organs. Specialised bone-largeling ¢anc¥r cells were acquired from collaboralors in Sheifield IProf8ssor Ingunn Flolen, previously held an ABC seed granti that wlll improve the study of bone melastasis. Docusign Envelope ID.. 5EB567BB_3EOA.48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT {Incorporatlng the Dlrectors, Report) fcon¢lnu•d) YEAR ENDED 31 DECEMBER 2024 Studylng early changgs In organ8 befor• cancer •pr•ad8 It was ftsund that breast lumours can influence distant organ8, like the lungs and bones, before cancer cells actually arriv￿ al Ih8S8 siles. 11 h8s beer) hypnlhesised that lumours help prepare these locations lo make them morel susceptible lo future tumour spre8d. In particular. it was observed that immune cells, especially neutrophils, incr8as8 in these "pre-melastalic oryans, showing early pr8paralion for cancer spr8ad. end a posslbl8 role for nBulrophils in thi8 process. Enhancing immunotherapy wlth metfomiin Further progres5 was made wSlh data $howing that the diabetes drng matformin improves the effectiveness of an￿- canc8r immune Iheraples, particularly in mi¢9 with diel-induced [￿9$11y. By studying lurnours from these mice, th& team found that melformln-tre8ted lumours in obese mlce had more cancer-fighling immune cells, called CD8 T- cells, which may h8lp Slow tumour growth. This is being pgrformed In collaboration with Dr Simon Lord. ABC Senior Research Fellow, Orièl College, Unlver8ily of Oxford. Invostlgatlng the impact of obe•lty on cancer progre*ilon Models of obesity for tha study of br8891 caiiLer wwe further charac18rised lo 8ngure that they 8re physiologically rel&vant and comparable lo human cllnical data. Advanced imaging lo measure 181 distribution in obese micg, revealed that increased fal li8su& corr8181es with higher Ivvels of fal-relal8d molecule8 iii Ili¥ blood. The9e molecules may contribute to Gancer progression, helping us undgrstand how ob8sily impacts canGer SPTead. Advancing antlbody.baJed cancer treatments Thg teams anliboéy engineering effort5 are continuing with the development of landerm Fc versions of Iherapeutsc anlibudie$. New v8r8ion8 were created and deslgned lo be mor8 stable wllh fewer sugar-ff laled isgugs. improving their 8ffecllvene55 ag8ing1 cancer and uselulness as 8 clinical therapy. Improved version5 Wlth special mulation8 ta boost their ability lo inl8r8cI with immune cells with enhanced cancer-flghllng ablllly were sludi8d. Studie8 into the d¥l8ile)Q structure ol these anlibodi85 using 8dvanced imaging techniques has helped the team understand how to make them work belter again81 tumours. Te8llng Innovativo antibody productlon mtsth(MSs (Ropliconl New ways of producing antibodies that would allow our bodie8 to make th& antibody in silu have been lesled. The Southampton 188m produced a special form of a canc8r largeling antibody using this new method, shDwing il works similarly to commercial v8rsions. Thu8 lar, Ihls has 1)nly been done in cells in th8 lab, bul this method could polenli8lly make drug produclionl admlnl8tration More efliciont. A8C •nqagom•nt Throughout 2024, the ABC Ther8peullc Antibody and ABC Oigcover teams conllnu8d to engage with supporters by 8llending even19 whlch have helped fLJrther foster connecllons between r888archers, funders, and the wider r.Dmmunily, rnany of whom have per90nal connections lo breast c8ncer. Th& University of Soulhamplon team participated Bgain in ABC'S 8nnual Breast Walk Ever, HAmpshire in May. Y4ilh severBI lab members volunteering as marshH15 and supporters. Grace did a sterling effort In helping orgar)i88 marshals at the unlversity end and achi8vgd some good promotion for th8 8vent including coverbge by the Univer51ty. the D8ily Echo and th@ Hampshire Chfonicle. Most of the University of South8mpton team presented al the ABC Re9earch Conference, June 2024. includin9 Dr Charlie Birts, Prof Max Crispin. Grace Haye5, Prof Paul Skipp, ar7d Dr Andy Shapanls. New Grant Incorne and Investment Max Crispin received new funding frorn the Bill & Melind8 Gates Foundation of £1 .4M over 2.5 year5, a 9ranl that will help support the Gore infrastructure of the group removing potential pressures on the ABC programme. Max and his Post4Joc Jo85 w8re also awarded $200,000 over 2 years from the Inslilule of pro18in design, funded by the Gales Foundation, lo further support the general running of the lab and r859arch environment. Collaborations Two Member5 of the antibody team. PhD slLMJent Grace Hayes and Anna-Liese Silber, visited the lab of Professor Ingunn Holen (previous holder of an ABC grant), Unlversily of Sheffield in April 2024 to receive training on inlracardiac injections to 851oblish an in vivo model of bone melaslasi5 in Soulhamplon, Another collaboration has been with Dr Slmon Lord. ABC funded Senior Research Fellow al OTI81 Coll8gg, Oxford on the polenllal use of melformin for breasl cancer. Doujsign En￿lOpe ID.. 5EB567BB-3EOA48C3-8E84_8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporatlng the Directors, Report) {con¢lnued) YEAR ENDED 31 DECEMBER 2024 Prof Max Crlspln named to ClJrivat8's Hlghly Cited ResearGh8r Li¥t 2024 The Clarivale Highly Cited Researcher list recognizes influential researchers at univer5ilies, research institutes and commerci81 organizations around the world who have demonstrated significant and broad influence in their f181dlsl of research. Max wa8 recognized the crossli8ld c81egory reflecting th8 broad range of tOPiC5 that hi5 research covers as a Professor of Gtycobiology. Max also m9de the list in 2019, 2022 and 2023. ABC posted a research news article about Max's achievement on the website. Against Breast Cancar Dlscover Programme Grant 2019-2024 Academic Staff.. Professor Paul Skipp, Profassor of Proteomlcs Senior Leclurer- Dr. Ben Nicholas Senior Fellow.. DT Andrew Shapanis- leaver to Xg8nera PhD Students: Dr Luls Coy- completedlle8ver to Xgenera Blabank updates All r8gulatory sl8p8 h8ve bean compleL¥d prior lo th8 ants'cipaled full Iransf¥r ol the Di81CompLyl biobank to Unlversity of Southampton from MTS Cryostores by 9th October 2025 R•••arch update Mr Lul* Coy- PhD student Luis successlully dclcndeo his Iliesis &riliiled 'Charactorising 8 3D cultur￿ Model nl Triple Negative Breast Cancer Through Syslpm%-BE]sed Molecular Phenolyping12181 June 20241. Accompanying Ihis report is the first p8per from his work, which 15 b8irig submitted for publication in International Joumal of Molecu18r Sciences ay part of a special issue 'Advances in Proieomics in Cancer.. Publlcatlon tltle: Proleomic Profiling Highlighis EnhanGed Drug Meiabolism and Oxidative Stress Response in Triple-N8gallve Bfeasl Cancer 3D Cell Cullure Models Lay xumrnary ot paper: Triple-negalive brea$1 cancer {TNBCI has a poorer prognosis than olher subtypes, with limited Ir8Alm8nl succ888. 3D cullure models, including th& ullra-low adherent IULAI sysl8m, beller mimlc Ihe lumour microenvironrnent bul remain under-ch8racleri5ed. The study used LCMSIMS to compare proleomic profiles ol TNBC cell lines in ULA and 20 CLJllur8s, revealing endched palhway8 in drug melabollsm and oxidakn've stress in ULA. Notably, AKR and CBR deloxlficBtion enzymes. along wllh antioxidants lik8 SOD1. PRDXS, PRDX6, arKI NXN, w8re upregulaled. Doxorubidn-Ire81ed HCC1143 celSs showed elevoled PROX6 and IDH1 gene5 in both models. underscoring anlioxidanl involvement in Irealmenl r88ponse. These findings highlight the ULA model's relevance lo chem()Iherapy resistance and its promi8e for ther8p8Lillc development. A further publication ig currently being drafted Ihal fotsuseg on Luis'g tran$crSptomic analyses of these trlple negatlve breast cancer 3D models. Dr Ben NiGhola8 Personalised vaccine development plarform Presenlallon of protein fragments by MHC (Major Hislocompalibilty Comp18xI to c811s of the immune system - including neoantigens - is an important mechanism Ic enable T-cells lo recognize and kill abnomial or cancerous cells. Dr Nicho185 is using sophisticated techniques lo develop neoantigen vaccines, by training T-cells lo identify lumor-specific mulalions and mount a largeled immune response. specific lo cancer cells. A5 part of a CRUK network accelerator, the leam developed a proleogenomic slralegy lo improve neoanligen identific81ion and achieved Immunogenic responses in 5 of 8 patients (80Yo). Ongoing work 15 focusing on the potential effect of phagocytosis ('cell eating,) and consequent high inlracellular lipid on IriK￿e negativ8 breast cancer efferocylosis (dying cell removal) and peptide presenialion lo T-cells by MHC molecules. This is important because TNBC presents unlque challenges for direct idenlificalion of T-cell n80ant￿9nS using immunopeptidomics. Some of these challenges are the high lipid environment and thg preponderance of 8pnptotlG turnour cells following chemolradiolher8Py. Docuslgn Envelope10'. 5EB567BB-3EOA-48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) (tontinu•dJ YEAR ENDED 31 DECEMBER 2024 Xgenera Devgloped through the A8C Discover programme, the mulli.cancer early datectlon lest, MIONCO. moved into the ommercialisalion ph8se through Ihe University spin-out company Xgener8, Th8 team secured a £2.5 M Nallonal Institute for Health and Rese8rch INIHR) 141 development grant as part of the Office for Llfe SclerKeg Cancer Mlsgion Its support clinic81 trials of miONCO. Dr Andrew Shapanis. th8 ABC Discover post-doctor81 research fellow has now Iran811ion8d full-lime lo Xg8nera lo continue Ihe development and commercialigalion of MIONCO. The DielCompLyf Biobank will 81so mak8 an Important contribution lo ongoing d8V8lopmenl of Ihe miONCO t881 upon 8rrival al Southampton Include lesling the polents'al of the lest lo d818GI early rg¢urrence of secondary bre881 cgncer. The miONCO early cancer detection lesl was reported in th8 noti￿al pre8$ (Oct 20241 with H8alth Secretary We8 Slre81ing Galling it a 'game changing ranGer test,. The A8C Oiscov8r tO8m 8ubmltled a manuscript 'Molecular phenotyplng of br8881 cancer d8fine& new 8ubgroup8 belonging lo thre8 clinically diglincl cluslèrg lo Breast Cancer Research. ABC Fellowshlp Programme, Oriel Colle9•. Unlv•rslty of Oxford Fellowship Start Dal8.' Sepl 2018 - Sept 2027 Academic Staff.. Senior R8s8arch Fellow - Dr Simon Lord Junior ReseBrch Fellow - Dr Lina Hacker Dr Simon Lord Research Raport Two pmjecls are desrribed whlch are pBrt funded by ABC. Prolect 1,. FRONTIER Trial Summary: Dr Lord a5 co-corresponding author submillad 8 paper lo Cell Melgbolism lin Oclober 20241 for Ihe FRONTIER study. Thls Iranslalional study uses dynamic functional Imaging in the clinic lo invesllgate how lumour cells melabolise amino acids such as glutamine as an import8nt Againgt Braast Cancer fundlng will be us8d locarry out largeled s￿qU￿￿e1ng ol common genetic 8lter8llons Ih818re known lo aller the metabollc phenotype in canc8r Imyc, PTEN, P13K, and p531, Prol•ct 2: Impact of ¢bo81ty on survl¥al outcom•s for cancer drug trovtmont Surnmary of proJ•ct: Over811 obesity is associated vAlh both 8 gre81er risk of d8veloping cancar and poorer prognosls. Conver981y, following cancer diagnosis, obese patients when compared to lean patients for some lumour sile5 have improved gurviv81. The reasons for this are not understood but 8xplanats.ons pul forward include Ihg poor health stslus of palier71s with a low body mass index IBMI} and possible in(xea$ed pffiGaGy of immunotherapy observed both in P8tienlg an¢ precllnlcal models. Additionally. BMI 15 a relatively poor rngasur8 of body cornposition which varies with age, sex, and ethnlclly. Th8 central hypothesi8 18 that there are v8riabl88 across lumour type5 including breast cancer which are more pr8diclive of Survival in obese compared lo lean patients. The alm is lo develop a multivarlable prognoslic model lo define whether 5pe&flc Irealm8nl cl855es end lifeslylelcomorbidilylfrailty f8clors beller a550ciat8 with improv9d survival in obese palienls compared lo lean palienls. The contribution of obesity lo patient survival will be evaluated for different lumour types and Ih8r8py cl8sse5. The ABC fellowship will fund contributions lo the proj8cI over the next 24 months. Dr Lina Hackgr, ABC Junior Research F911 Junior Research Fellow. Dr Lina Hack8r has had a highly successful lirsl year al Oriel College, University of Oxford. Or Hacker is researching phot08couslic imaging. which uses a combination of light and sour)d, as a novel non- invaslV8 method for the early detection of br&asl cancer. 8y identifying signals Ibiomarkers> related to Varying hypoxia in breast cancor She is aiming lo help doctors beller Docusign Envelope ID.. 5EBS67BB-3EOA48c3.6EB4_8BDE71138265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT {Incorporating the Dlrectors, Report) (contlnuBdJ YEAR ENDED 31 DECEMBER 2024 underslan(J the aggressiv8ne5s and reslstance of tumours and choose the best trealm8nls for pahonls. In January, she wag invi18d lo the US Food and Drug Admlnistralion in San Francisco to discuss ways lo bring novel 88rly detection like pholoacou8tic imaging into cllnical practice, Dr HaGker also received 8 2024 Award for Excellence from th8 Oxlord Univ8r5ily Oncology Departm8nl as w811 as the C8ncer Researth UK Bridge lo Academlc Legder5hip Fellowship for s8lecled early re8earcher5 lo support their transition lo independent group leaders in cancer research. Athjitionally, Lina was selected as Fellaw by the German newspaper"Die Z8il" (The Times) lor Iheir"Zia- Visible Women in Science Program Dr Hacker also presented her re$o8rch at nin8 conferences and had elev8n peer-reviewed papers published in scientific journals. Dr H8ckerfs efforts lo support gender equality in science, technology, engineering. and m8lhemalics ISTEMI gubjecls were 8lso r8cognized 81 the Llnlted Nallons conlerence on the Comrnission on the Status of Women (New York, March 2024) by UN Women UK with an appointment as a delegate. Lina h89 become 8 greol advoc81e of the ch8rfty too, finding the lirne in July lo present har work to 8UPPOrter8 81 our first ABC Research Conference. In S8plember she onc8 8g8ln volunte8red har Ilme 88 a mar8hal, lookSng aft&r our supporters as Ih8y Inak part in the Br8a51 WBlk Ever. Oth•r •ngagDm•nt with Orlel Fello Dr Hackor has kindly agreed lo at18nd an ABC fundraising event being ho8led by 8arclays at Christ Church College Oxford. Rob, Mark. Richard and Amb8r will also be in all8nd8ncg with i Phone Idunaled by Ak8misBiol card readers Iri lake donations durin(J H ralfl Other research actlvltlei.. ABC have b8en supporting p8llent public involvement IPPII studie5 Wlth a combination of our website pag8'Take Part in a Fiv8e8rch Study, and by posting on social rn8di8 {8ryonyl sites Linkedln, Facebook and Instsgram. Studies SUPPOrted inGlude'. TADPOLE study- Inveslig81ing whether tsrgeled axi118ry dissection ITADI of cancer affected lyrnph nodes is as eff8Ctive 89 AKillary Lyrnph Node dlsseclion (ALNDI or Axillary Node Clearance IANC) but fewer side effects. Prof Ramsay Culre99 Is 8 co-lnvesligalor on the TADPOLE Study NIHR Patlent Engagement In Cllnl¢al Dev•lopmqnt (PECD) Service are looking for palienls or carers wlth experience of mel85181ic brea81 cancer land other cancersl Rob Fleming and Mark appe8red on the 'One-lump or two, Podcast that was broadcast Mark as Rese8rch Manag8r allended two AMRC Meeting in London 16th July 2024 wSlh training and best practice advic8',- R8search Funding Essentials and Research Impact Mark, Dr Harmer and supporter Karen Hockey, attended the Support the Supporter5 Event in London which raised money for ABC Mark will attend the Medical R8search Charity Showcase.. House of Commons, 21st January 2025 Lunch in Decerviber with local Freemasons lo receive fundraising cheque from prevlous Plg Racing event Looking ahead to 2025 and beyond 1. ABC Dljcover 2 grant pr(Jposal 2024-2029- Professor Paul Skipp, University of Southampton Docusign Envelope10'. 5EB567BB_3EOA48C3-8EB4-8BDE7713B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporatlng the Directors, Report) (contlnuod) YEAR ENDED 31 DECEMBER 2024 Charlly report SportB & Chall•nge 2024 has presented a period of significant growth. Revenue in 2023 w85 circa. £270k, at the lime of writlng In Dec8mber 2024. the figuro) $1811ds al c)ver £320k. The demand shows no signs of 81owing with naarly 89 m8ny12211 already signed up for 2025 events as have participated in 202412231. Given the Inc￿8S1￿g levels of demand, we have continued our pursuit of aulomalion, This includes thè synchroni5ation of enquiry forms from our websi18 dir8Ctly with our databasa.. dynamics- hugely helping lo improve support8r slewardshlp. We are looking al how we can hamess the pow8rs of the forms within our website to avoid reliance on thir¢ partles for event sign-up. merchandise sales and fundrai¥ing pag8 crealian. We have piloted the use ol iRai88r for 8re85t Walk Ever Hampshire with th8 intention of maxlmlsin9 funds raised al the p)int of engag8ment, A Icl has been188med as we further explore the capabllltles of our webslle lo do this for us, Marathon M8prs W8 were alloc8led just 12 places this year for London Marathon rather than th8 20 we have h8d previously. Our learn comblned to rai88 a quite 31aggering £47,000 belween them. W8 understand thing8 ar8 shifting wllh the allocation of London M8r81hon places across the charity sector in the comlng years. London and the maralhon majors prgsenl 8 major Income source 8nd will demand serious allenlion. The d¥mand for the Six world MarAlhun Mdjors" is huge and something we can certainly benefit Irom. The 2024 Berlin Marathon team raise(l over £44.000 between 2fj iunneTS f()r ex8mple. We are working lo d81ivar all th8 Abboll World Maralholl Majors in limp with ihe rpcenl Bcquisilion of places in Chicago, New York and Tokyo. To go with Berlin and London. We ar¥ hopiiig ID acquire places for th￿ "s8venlh major" Sydney in 2025. We continue to use google 8d5 effectlvely to benefitfrom increased demand for European marathons. Breast Walk Evar Breast Walk Ever Hampshire 15 going from strength to Strength with the 2nd edition taking plACP. nn Sunday 12th DI May., raising just under £30k. We w8r8 loined by a good number of researchers and professors from the University of Southampton who marghalled v8rious points on the course. Fund8 ra18ed from tho Oxfordshir8 walk In Seplernber ensured that well over £50k was raised from the 2024 BWE sories. Community fundral*ing Club & Lady Captain's 81 Sandford Springg Golf Club héld varlous events IhroughoLJt th8 year raising a fantastic £20k in the process. The charity will altend the handing over of the captaincy at Ihg club in January 2025 when funds raised are expected to r88ch £25.000. 8811ey Bul￿dOgS held Ihelr annu81 Play il pink event and ralsed an amazino £5,000.00 Charity Ang81s contlnued their lanla81ic fundraising throughoul 2024, hosting a f85hlon show in Sevenoaks that raised £13k 89 well as a dinner al the Army & Naby club In Pall Mall that brought in over £15k. The organisation hove now raised over £100,000 for the charily. CoTporatE SUPPCrt We benefilted onc8 again from a very generous donatlon 01 £1 Ok from Llbman. A h8ndful of current corporate P8rtner5 alsn donated 5_1 OQh of the 581e of Specific Items during October18reast Cancer Awareness Month>. The revlew Into partner5 still engaged continues inlo 2025 when we geek ID create new lastina ￿l8110n$hlp$ whilst nurturing 8xisling ones. R•tall Compgni8s ordering large quanlilips of fundraisi1￿ materials h8ve been passed on ID the fundraisin9 manager to discuss ongoing partnerships. this w88 parliculady common during Brp8sI Canc8r Awareness Month Christmas cards have onG8 again been popular and include 8 br8nd new design lor 2024. Christm85 bundles have also b8en piloted on the shop whilsl we Continue to work with"Cards for Good Cause8" who give the prO￿edS fomi the Sale of varlous dosigns to charlly. Throughout 2025 we will invite 5UPPOrters lo send their photos to create a 2026 Against Breast Cancer Calendar using the 12 best phalos. Important date8 relevant to the charity will be highlighted in the Calendar. Docuslgn Envelope 10.. 5EB5678B-3EOA_48C3.BEB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) (contlnuadj YEAR ENDED 31 DECEMBER 2024 Dèv•lopment 2024 was our busiest year of administering charitable e91ales on record. More supporters Ih8n aver d8monstraied their support by choosing to leave a gifl in Iheii Will to Against Breast Cancer. This cainclded with the launch of our 5 yaar strategy to 8UPPOrt the acquisition and growth of Supporters who hav8 pl8dgad lo leave a gift in Iheir Will. We have appoinlad partner organlsalions, selected for their depth of knowledge, reach and experience of th8 sector. Smee and Ford provlded insight and analysis of the current glfts Sn wills landscap8. Our go81 is lo18ver8g8 thi5 data lo develop a national marketing campaign. Octopus Legacy have b8en appointed 8$ our primary free wills partner. By raising awa￿ne$S of glfts in wills and legacy giving. we can engure a steady stream of fundlng for yaarg 10 come. Our flrsl campaign wlll be In SpTlng 2025. We once again succes8fully applied for funding from the Early-career researcher support fund. Thls application resulted in B donation of £142.511 Funds gen8raled through our rnailings and granl 8ppIic81ions mad8 lo charilablc Trusts anil Fouriilaliori.4 rpiYiAin steady despite being becoming a highly competitive sector. We were grateful lo Ihe Enl8rprise Mobility Foundation for their gift of £10,000 Digital Efforts to improve the vlslbilily of the webslle online hava be8n succ8&sful. By focussing on vi8ltors wilh 'hioh intent, rather than a high volume of IrafflL, we hav& priorilised quality over quanlily. The objective was lo 8tLr8cI an uplift in engaged visitor5 coming lo the webslle. More engaged vlsllor5 can be expected lo spend morp lime on a website and are more likely lo take an 'aclion' IdDn8te, download, apply elc.). The result saw the website being responsible for a significant incrga$e in Ihg number of individuals contacting us wllh a vlew lo taking part in one of our featured evenis. We were abl& to mitigate tha addillonal 8dminislralion created by the incraase in applications by 8ulomaling our back office procedures. Thls was a huge slep lorw8rd lor the charity, saving a consid8rable amount of time for all concerned. In addition to linking to the charity database, the website can also now directly process paymants wilhoul th8 need of 8 third party supplier. Together. these steps h8ve significantly improved the conversion of applicolioris becoming supporters of th8 charity FINANCIAL REVIEW During th8 financial year ended 2024 Against Breast Cancer continued lo remain committed to achieving its objeclives in support of financial growth and stability despite a challenging economic environment. As a result, a profil of £104,179 was made in 2024 compared to a loss of1£63,2081 In 2023. Throughout the year a continued uplifi could be 58en in fundraising with events being at it5 stronge51 post pandernlc and legacles showing an upward movem8nt in revenue performanc8. This is reflecl8d in th8 con501idat8d income for 2024 being £1,024,382 in contrast to 1,026,990 in 2023. The charily15 moving even closer to meeting ils income growth strategy of increasing inGome to £1.5 million in the next four yearg, so enabllng further Spend on research. DO￿J$Ign Envelope ID.. 5E8567BB-3EOA-48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) (continued) YEAR ENDED 31 DECEMBER 2024 The research expenditure for the year cunlains a credit repayment of £196.884 in respect of an undergptsnd on the 5 year Discov8r Pfojecl. The Tru818es Intend to relnvesl these funds in the ongoing research of the Charity. Following the funded research of tha Dielcomplyf study al the University of Weslminsler in 2015 the chafity developed a r8se8rch strategy funding lono term and short-term innovative rèsearch projects. In addition to our long term core research we also fund PhD's and Junior Research F8llowghips for the advancement of education through teaching and ragearch. Thes6 projects are I￿r￿ed responsibly in line with Against Breast Cancar objectives, and surplus funds ring fenced annually for further spend on research proj8cts and lab equipment. The res&arch strategy and charity long lemi projections see responsible, sustainabl8 and substantS8l growth in funding in line with projected growth In Income and maximising ROI. Against 8r8as1 Cancer canlinu88 lo work with the dinical sponsor of the DieiCompLyf study. Unlversily Collage London, lu pul proces88s In pl8c8 to rn8ke the dal8 ond 3ample5 from the DielCompLyf evBilable for further r￿s￿arch. Against 8re8sI Cancer ha5 a projgcled long-lem regearch portfolio in 8xce9s of £4million. This portfollo has been ste8dily built in line with the researoli Slratggy and Charity long 18rrn proj8clions en3Ufing su31ainBbilily for the future. PLANS FOR FUTURE PERIODS Pl8ris 8r8 in place to work wllh l898cy fundraising partners lo help us understand our supporters b8tler. This wlll inform how best to communlcale wllh different gegmenls and how we might attract new audience5. Our brH bbiik holders present a key 8re8 of focus for 2025, Engaging them as Champions" of Aqainsl Breast CBncer prescnls a key 51ralegic aim for 2025 as we 5£1ek lo reward their loyalty and harness their enihusi8sm lo sprp.ad Ihe wnrd of our research in their communities. Wg are partnering with Octopus L8g8cy in March lo launch a "Free Wills campaign. The inilialive will include inveslrnent in advgrt18ing via social media. Knowledge gained from our work with Sme8 & Ford, will inform OUT decisions on where best lo largel. The intenlion is lo allract people who are most likely lo leave 8 gift ii) their will. 2025 is B year very much rnarked for gro￿ In our retail department. We are making an investment in inventory management goftware, Unleashed, lo ensure efficiency across our various plattomis and rigorous slock conlrol. Community fundraiging will have greater regoufce in 2025 also, with v8rious naw campaigns and evenlg planned. We a￿ enllsting th8 help of 8 Ioc81 communlly group to freshen up Splash Df Pink, We are also planning a Chfislmas carol event in Abingdon m8rkel square for December and 8 Summer awaranesg campaign Iocu9ing on br&ag1 cancer in men. Charily Aiigels have elected lo continue lo support ABC again in 2025. They are busy plannlng their Calend8r of eclivity which includes a Breast Walk Ever evenl al Sl Clere estate in Kent in June 2026. REGULATORY COMPLIANCE Trust895 conllnue to play an active rd& in tho adminislralion of the ch8rity. ensurlng we ere accounlablo lo everyone with an inter851. They ensure the charity's resources ar8 managed responsibly and in accord8nc8 With current legislation. The trustees abide by both the Code of Fundraising Pra¢ii¢g and the Charity Governance Code to ensure best P055ible practice in their g¢)vernance of the charity, STRUCTURE, GOVERNANCE AND MANAGEMENT Governing Document Against Bfftasl Cancer Limile(l is 8 Gompany limited by guarantee and regisler2d 85 a charity. T*e goveming document of the charity is the Memorandum and Artides of Association issued 11 July 2007. Governlng Body Overall respor)sibilily rgsts with the Board of Trustees who are also appointed as directors ol th8 charitable comp8ny, Authority from the Trustees is delegated to the Chief Executive ICEOI, Bernadette Jones, who is responsible for the day lo day management of the charity's affairs and for the implemenlalion of poliGie5 agreed by the board. The 10 Docusign Envelope10'. 5EB5678B-3EOA-48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) (conllnued) YEAR ENDED 31 DECEMBER 2024 CEO 18 a5SlSted by a management leam, staff 8nd volunteer5. The board approves the delegation of financial authority through the CEO. with speafic limi15 irnposed within an approved scheme of delegation. Recruitfflent, Appolntment, and Training ol Trustees The appointment of Trustees is made In accordancg Wlth th8 Articl8s of Association which include$ the receipt and appioval of an application for membership. The s8leclion of Trustees ig designed lo supplement th8 existing skills and expertise of the Board and is govemed by an informal sk1115 assessrnenl. The Tru81888 recognise that a more formal approach should b8 taken in respect of their induction and training, p8rtscularly a5 regards lo naw appointm8nls. and procedures are being formulated this year. This includes the dgclaralion of eligibility lo serv6 a8 a Tru8te8 including nolificalion of any potential conflicts of interest. Currently Against Brea$1 Cancer Limited has eight Iruslèes. Together they provide a broad range of skills and eKP&rtis8 that the trustees want represanled to 8nsure a strong board Ihese include scientific and medical backgrounds, strategic thinking. financial and organisalional management and markeling skills. In addition, many of the trustees h8V8 personal experlence of the impact of braasl cancer on peopleg, lives and so are empalh8lic lowar(Is the goals ol the charity. Organls•tlonal Manag•m•nl The Iru$l88s have legAI respJn$ibility for the Strategic direction and eff8ctsve governance of Ihe ¢harily. The Irusla8s, also being directors of the company, who served during 2024 are listed on page 12. On average the board meets lour Ilmes a year. Group Structure and Relatlonships The charily lia8 a whc)Ily r)wned sub5ididry. Against Broa81 Cancer I fradingl Limited, fftglster￿d in England number 6J10215. The subsidiary operal&s from i)reniises leased by Ilie charitable Lumpariy and sells promoliDn¥l item5 bearirbg the Against Breast Cancer logo. 11 donates ils taxable profits lo the charitable company. Against Breast C8ncer achieves ils objective of commissioning research through its close relallonshlp wSlh a rasearch team based al University of Soulhampton, and 8 research team based al the University of Oxford. The charity provides a grant lo each 188m which fundy their 5818ry and labor8tory costs and en8bles the ongoing research lo take placa. Ag8insl Breast Cancer also esl8blished a Fellowship programme in 2014, to support rising scienlilic laleiit in Ill breast cancer researLh field. The first 3-year Fellowship is associated with Oriel College, Oxlord, E)nd was awarded lo Dr. Max Crispin who Is daslgnlng new lieatmenls for mttl8slalic brv.asl cancer. Following on from this Fe51uwship, in 2018 Against Brea81 Cancer with Oriel College sel up a 9 year ABC funded Junior Fellowship programme to conlinv8 advancements of education Ihrough leaching and research. Re$orve8 Pollcy Against 8re8St Cancer decided on a policy of holding 3 to 6 months operating costs. A figur8 of £150,000 was considered lo be a reasonable level ol reseNes lo be held that would enable the charity to meet all of ils liabilitie5 should operallons have lo cease al some poinl in the future. Thls includes all c0518 such as redundancy for employees, professlonal fees and a wind down of the researGh programrne. A5 81 the 31 st December 2024 the gTOUP held net current asse15 of £266,113 wathin its total reserves of £458.168, of this amounl £10,000 was held as ￿$trICted. Free reserves of the Group as at 31 December 2024 were £122.87612023: £33,830) Risk Manag8ment The major risks, to ￿1¢h the chanly is exposed, as idents'fied by the Trustees, hav8 been r8vi8wed and systems have been eslablishad to miligala those risks. REFERENCE AND ADMINISTRATIVE DETAILS Reglstered charlty nam• Against Breast Cancer Limited Charity rggistration number 1121258 Company registratlon number 6310215 Docusign Envelope10'. 5EB567BB-3EOA48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporatlng the Dlrectors. Roport) (conttnued) YEAR ENDED 31 DECEMBER 2024 Rogigterod offic L&8them Flouse 13 Napier Court Barton Lane Abingdon Oxon OX14 3YT Tho trust9?• The trustee8 who 80Tved th8 charity during the perK)d wer8 88 follows.. Mrs J Chattoe Miss V Hamier Miss N A L Webb Mr R B8hu Mrs L Hounam Mrs J Collin8 Mr O Rgmounda8 Auditor Xeln8dSn Audlt Llmiled Chartered Accountants & Slalutory Auditor Beckell House 36 Old Jewry London EC2R 8DO AUDITOR Xainadin Audlt Limllgd arB deemed lo be re-appointed under seGlion 487121 of the CompanieB Act 2006. TRUSTEES. RE8PONSIBILITIES STATEMENT Tho trustees (who aro also the directors of Against Breast Cancer Limit8d for the purpose5 of company lawl aro responsiblo for prep8ring th8 Tru81888 Annual Report and the Ilnancial statementB In 8ccordanc8 with applicable law and rogulats'ons. Company 18w requir85 the Irusle8S to prepare financial statements for egch financial ye8r. Under that law the truglees have elected to prepare the flnancial statements in attordarice with Unit8d Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standard5 and applicable lawl. Under company law the Iruslees must not approve the financial Statements unless they 8re satisfied that they give a true and lair view of the state of affairs of the charity and the income and expendilure ol the charily for Ihat periud. In preparing these financi81 statements, the trustees are required to.. select sullable accountSng polScles and then apply them consistently; obserye the melhoés and prlnciples in the Charities SORP., m8ke judgements and accounllng e5tlmates that are re280nable and prudent; and prepare the financial statemen19 on the going concem basis unless it Is inappropriate to presume that the charlty will Gonlinue in operation. The Iruslees 8re responsible for keeping 8dequ8te accountillg records that 8re suffici8nl lo show and explain th8 charity's Irans8clions and disclose with reasonable accuracy at any lime Ihe financial po3ilion ol Ihe charity and enable them lo ensure that the financial statements ¢omply with the Companies Act 2006. They are also responsible 12 Docusign Envelope ID-. 5E8567BB.3EOA48C34E84_8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporatlng the Dirnctors, Report) (eoniinu•al) YEAR ENDED 31 DECEMBER 2024 for saf8guardlrvJ the as99ts of the charity and honce for taking reasonable s14Js for the preventlon and delection of fraud and other Irreaularities. STATEMENT A3 TO DISCLOSURE OF INFORMATION TO THE AUDITOR Eath of the persons who Is a trustee at the date of approval of this mpt)rt ¢onlrms that so far as each Iru81ee 15 aware. Ih8ra IB nu relevant 8udil information of whlch the charlly's auditor ig unaware- and each truste8 has taken all sleps that Ih8y ought lo have tak8n as a trust88 to make themgdf awar& of any ralavant audit information and to estab118h that the th8rity's auditor 18 awar& of th81 information. SMALL COMPANY PROV1810NS Thi8 report has been prepared in accordance with the prov181ons appll¢able to compani8s entltled lo the sm811 companies exemption. Reglstered oifice.. L8alhem House 13 N8pier Court Barton Lane Abinqdo Oxon OX14 3YT Sign8d by order of the IrusteeB R Bahu Tru8lee Director 24 Soptember 2025 13 DooJsigr4 Envelope ID.. 5E85678B.3EOA48C3_8EB44BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF AGAINST BREAST CANCER GROUP LIMITED fconllnu•d) YEAR ENDED 31 DECEMBER 2024 OPINION We have audited the financi81 statements of Again8t Breast Cancer Limited Ilhe 'Parenl Charitab18 Company'l and its subsidiarie5 (the 'Group'l lor the year ended 31 December 2024 on pages 17 to 32 which comprise the Group Statement of Financial Activllie5, th8 Group Summary Income and ExpendSlure Account. the Group and lh8 Parent Charitable Comp8ny Balance Sheel, the Group and the Parent Charitable Company Cash Flow Statement and related note$. including a summary of significant accounting policies. Th8 financial reporting framework that has been applied in their preparatlon Is appllcable law and United Kingdom Accounting Standards, includSng Finanual Reporting Standard 102 The Financial R8POrting Stsnd8rd applicable in the UK and Republic of Ireland (United Kingdom GenerBlly Acc8Pted Accounting Practice). In our opinlon.. the financlal statements giv8 a true and falr view of the slat8 of the Group's and Parent Charitable CompanV8 8ffair5 88 8t 31 D8C8mber 2024 and of the Group's and Parent Charily's incomlng r8sources and applicalion of resources, including its income and expendllure, for the year Ihen ended- the financial g18temenls have been properly prepared in accofdance wllh Unlted Kingdom Generally Accepted Accountlng Practice; the financial statements hav& been prepared In accordance with the Companies Act 2006. and the Charitie¥ A¢1 2011.. BASIS FOR OPINION We CDnducted our audit in accord8nce with Inlernalional Standards on Auditing IUKI IISAS IUK}l and applicable law. Our responsibiliti88 under Ih05e standards are further described in the Auditor's responsibilities for the audit of the fin8ncial st8lem9n19 9eclion of our report. Wa are independent of the group and parent charltable company in accordance with the ethical requiTemenl8 th81 are ffjlevanl lo our audll of the flnanclal slalernents In the UK, including th¥ FRC'S Ethical Standard, Bnd we have fulfilled our other elhlcal ffsponslbililies In accordance with these requlremenls. We beli8ve that the audit evldence we hgve obleined is sufficient and 8ppropriate lo provide a basis for our Jpinion, CONCLUSIONS RELATING TO GOING CONCERN In auditSng the fSnanclal statements, we have concluded that the Iru$l8es' us8 of the golng concern basis of accounting In the preparation of tho Ilnancial Statem￿t9 is appropriate. Based on the work we have p8rform8d, we have not Sdentlfted any malerlal uncertainties re181ing to evgntg or conditions that. Individually or collectively, m8y cast slgnific8nl doubl on the Group'$ or Parent Charit8bl8 Company's abilily to continue 88 a going concem for a perlod of at least twelve mcnlhs from when Ihe flnancial 51alernent5 are oulhorlsed lor issue. Our responsibilities and the responsibilities of the trustees with respect lo golng concBm Bre d8gcribed in the r818vant sections of this report. OTHER INFORMATION The other information comprises the Informal￿n included in the trustees, annual report, olher than the financial glalements and our audilor's report ihereon. The trustees are responsible for the olh8r infomation contained within th8 annual report. Our opinion on the flnancial slat8rn8nls d089 not cover the other informalion and, except lo the exlenl otherwise axplicilly stated in our rnport. we do not express any form of assurance conclusion thereon. In ￿nnectIOn with our 8udil of the financial stalem8nts, our responsibility is lo read the other information and. in doing so. EDn5ider whether the other information is materially incon5islenl with the financi81 statements or our knowledge obtained in the audit or otherwise appears to be materially misslaled, If we identify such matenal inconsist8ncie5 or appafftnl material misstalemenls. we are required lo determine whether there ig a material mi5slatement in the financial 51aletnents themselves. If. based on the work we have perform8d, we conclude Ihat ihere is a materi81 misslalement of this other information., we ere required lo report that fact. We have nothing lo report in this regard. 14 Docusign Envelope ID.. 5EB567BB_3EOA48C34E84-88DE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF AGAINST BREAST CANCER GROUP LIMITED (contlnued) YEAR ENDED 31 DECEMBER 2024 OPINION ON OTHER MATTER PRESCRIBED BY THE COMPANIES ACT 2006 In our opinion b8sed on the work undertaken in the course of the audit.. the infomi81ion given in the Tnjslees Annual Report lincorporaling ihe directors. report) for the fina￿la1 year for which the financial statements are prepared is conslstenl wllh the financial statemen15 the dlreclors. report h8s been prepared in 8ccordanc8 wilh applic8ble le981 requirements. MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION In the IKJhl of our knowledge and under8t8ndlng of th8 Group and Parent Charitable Company 8nd ils environment obtained in the coursv of 1118 audit, we have not identified materigl migsl8temenls In the direclor8' report. We have nothing lo report in respe¢l of the followng mallers where the Compani88 Act 2006 and Ihe Ch8rilies Act 2011 r8quire8 US to report lo y()u if, in our opinioll.. Th& PaTrnt Charilab18 Company has not k8pl adequ81e and sufficient accounllng r￿OrdS, or relurr)s adequate for our avdil have not been received from branches not vlsiled by us; or The Parent Ch8rit8bl8 Company financial sIBlements are not in agreement with the accounting record8 8nd relums., or Certain disclosures ul directors, remuneration specified by law are not made., or We have not received Bll the Informati￿ and explanations we require for our audit- or The Trustee5 were not enlilled lo pr8par8 Ihe financial $1818menls in aGGordance with the small companie8 regime and tBke advantage of thg small companies exemplion from the requirement lo prepare a slr818gic Teport RESPONSIBIL￿lEs OF TRUSTEE3 As explained more fvlly in the Iruslees, responsibilities st81ement Iset out on pages 12-131, the Irusl888 (who are also th8 directors ol the Parent Charilable Company for the purposes of company lawl are responsible for the preparation of the linanci81 slalements and for being 5alisfi8d that they give a true and fair view, and for such Internal control as the Irusiees deiermine is necessary to enable the prep8ralion of finan¢i81 $tat8monl$ Ihat are free from material misstatement. whether due to fraud or error. In preparing the financlal slalemenls, the Irv$lee$ are regponsible for assessing the Group's and Parent Chbrilable Company's ability to continue as 8 going concern. dlsclosing, as Applicab18, matters relat8d to going concern and using the going concern basis of accounting unless the Iruslees either intend lo Iiquidale the Group or the Parent Charitable Comp8ny or to cea8e operatsons, or have no realist1¢ alternative bul lo do so. AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS We have been appointed as auditor under section 151 Charities Act 2011 and under the Companies Act 2006 and report in accordance with regulations made under those Acts. Our objectives are lo obtain reasonable a55ur8nc8 aboul whether the financial 51alernents as a whole are free from material misstalemenl. whether due lo fr8ud or error. and to issue an audrtor's report that Includes our opinion. Reasonable assurance is a high level of asSUTance, but is not a guarantge that an audit conducted in accordance th ISAS (UK) will always delecl a material migslalement when il 8xists. Misstalemenls can arise from fraud or rror and are considered material if, indivldually or in the aggregate. they could reasonably be expected to inlluence the economic d8Gision5 of users taken on the basis of these financial statements. Irregularities, including fraud, are instances of non-compliancg with law5 and regulation5. We design procedures in line with our responsibilities, outlined above, to deteet material mi$slalemen15 in respect of irre9ularilies, ir¢cluding fraud. The exlenl to which our procedures are capable of detecting irregularities. including fraud Is detailed below. 15 Docuslgn Envelope ID.. SEe567BB-3EOA-48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF AGAINST BREAST CANCER GROUP LIMITED fcontlnuedj YEAR ENDED 31 DECEMBER 2024 We obtalned an under818nding ol the legal and regulatory frarneworks that are applicable to the enlty and delermlned that the most significant are those that r8late lo th& Charities SORP, Charities Act 2011, Compani8S Act 2006, Code of Fundraising Practice and data prot8Ction laws (including UK General Data Protection Regulatic {GDPR)I We assessed the risks of m8leri81 mi8818temenl In respect of fraud by Making anquiries of managemant and those charged with Governanca Raviawing fraud dsk factors within di8CU88ion of related party rel81ionship& and iransackn'ons Bas8¢ tsn the results of our risk 8s$88sment we d6slgnad our audit proc8dure51o Identify non-compliance wllh such 18W5 and regulations iéenlified abov8. Th6 Group's and Pargnl Charitabl8 CDmp8ny's policlos and procedures for compliance with Ihose18ws and re9uIBlions w88 ob13in8d 8nd discussed with management. We COfrobor8ted our enquirie9 Ihrough r8viw of board meoting minutes and reports. No contradictory 8VKlence wes identified. We con51d&red tha rlgk of fr8ud through m8n8g8ment override and. in respon88. we Incorporated tesling of rn8nual journal entries throughout the year and accounling estim81es at the year end into our audit approach. B838d on the fesulls of our ri8k as8ey¥IN¥nt wp desigr7ed (xjr audit procedures lo Idenllfy and to address m8teri81 misslal8m8nts in relation lo fraud Including a review of th& accounting policies adopted by the Group and Parent Charitable Company particularly in relation lo the recognition of inccme. Wg havg consid8red the exlenl lo which the audit was considgred capable of deleclinq irrellularities which Is inherently difficult when d￿aling willi In(:iJniiiig resources frum dnnalions. Tliv. PArviil Charilable. C()mpaiiy's inleriial Gonlrol procedures have been designed lo mitigate 8gainsl Ihis risk. Because of the inherent Ilmilations of an audll, there Is a rlsk that We will not delact 811 irregularities, including Ihosa leading to a material mi581at6menl in the financial slalements or non-compliance with regulation. This ri8k Increases thg more that compliance with 8 lew or regulats'on 18 removad from the events and Iran8a¢lion8 reflecled In the flnancial $18lemenls, as we will be l&ss likely lo becoma aware of instances of non-compliance. The r18k 18 also greater r8garding Irreguladlios occurring due lo fraud r8lh8r Lhan error, as fraud involves intentional concealment, forgery, collusion. omlsslon or misrepresenl81ion. A further description of our ie8ponsibililie8 for the audit of the flnanclal slataments Is located on the Financlal Reportlng Council's webslle 8t.. vmw.fro.ory.uklaudllorsre8ponslbllllieg. Thi$ description forms part Df our auditor's report. USE OF OUR REPORT Thls r8POrt Is made solgly 10 the charllable company's members, a8 a body, In accordance wilh Chapter 3 01 Part 16 of the Compani89 Act 2006. Our 8LMlil work has b8en undertaken so that we might slate to the charitable company'5 members and Iruslees those m811ers we 8re required 10 8tal8 lo them in an auditor's report and for no other purpoge. To the fullest extent p8rrnilted by law, we do not 8Gcept or assume re5ponsibilily to anyong other thBn th8 charitable company's members 0$ o body 8nd its Iruslees as a body, for our audit work, for this report, or for the apinions we have formed. OoayS1gnod tsy.. 2D7 OAC azel￿aY ￿¥C￿40ns1 FCA DChA (Senior Slalutory Auditor) For and on behalf of XEINADIN AUDIT LIMITED Chartered Accountants & Sletutory Auditor Beckett House 36 Old Jewry London EC2R 8DD XBlnodln Audit Llmlled 1$ dIg￿le lo act 83 an Budsior In ierms ofsÈclion 1212 of Ihe Compan￿$ Act 2008 16 DocusMJn Envelope ID.. 5EB567BB-3EOA48C3.8EB4_8BDE71138265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 DECEMBER 2024 Unrestricted Funds R•Atrlcted Funds Total Funds 2024 Total Funds 2023 Note INCOME AND ENDOWMENTS Donations and legacies Other trading aclivities Inveslm8nl incomo Other income 855,312 185,540 2,077 35,628 890,940 185,540 2,077 841.838 266,098 2,117 TOTAL INCOME 1,042,929 35,628 1,078,557 1.110,053 EXPENDITURE ON Raising Funds Charllable activitles Other {661,671) (247,320) 129,759} 1938,7501 (661,6711 (282,9481 (29,7591 (974,3781 1610.7701 1545,0431 117,4481 11,173,261) (35,6281 TOTAL EXPENDITURE (35,6281 NET INCOME AND NET MOVEMENT IN FUNDS FOR THE YEAR RECONCILIATION OF FUNDS Total funds brought forward TOTAL FUNDS CARRIED FORWARD 10 104,179 104,179 {63,2081 343,989 10,OUO 353,989 417,197 448,168 10,000 458.168 353,989 The SIAlvrn8nl of Financial Activities Includes all gains and Ios589 in the year and therefore a slal6menl of lotBI recogniged gains and losses has not been prepared. All of the above arnount5 relate lo continuing aGlivilies. The notes on page5 23 to 32 form part of theja financial slalements. 17 Docusign Envelope 10.. 5EB5678B.3EOA.48C3-8EB4.8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 DECEMBER 2024 Unresffictod Funds Restricted Funds Total Funda 2024 Total Funds 2023 Nole INCOME AND ENDOWMENTS Donations and legacies Other trading 8clivSlles Inv85tment incom• Other Income 938,436 3,849 2,077 80,000 35,628 974,064 3,849 2,077 80,000 1,031,246 805 2.117 65,0(￿) TOTAL INCOME 1,024,362 35,62 1,059,980 1,099,168 EXPENDITURE ON C05t5 of generating funds.. Costs of raising donations and legacie5 Costs of charitable activities Other (847,3761 1247,3201 (25,487) (920.183) {047,376) 1282,94BI 125,487) 1955,8111 1603,0051 1545.0431 (14.3281 {1,162,3761 (35,6281 TOTAL EXPENDITURE {35,628) NET INCOME AND NET MOVEMENT IN FUNDS FOR THE YEAR RECONCILIATION OF FUNDS Total funds brought forward TOTAL FUNDS CARRIED FORWARD 10 104,179 104,179 163,208) 343,989 10,000 353,989 417,197 448,168 10,000 458,168 353,989 The Sl8t8m8nt of financlal actlvllles includes all gains and1055es In the yeBr. All of the above amount8 relate to continuing acuvllles. Tho nct83 on pages 23 to 32 form part of th•s• financial statgments. Docusign Envelope ID.. SEB5678B_3EOA46C3_8EB4-8BDE71138265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CONSOLIDATED BALANCE SHEET 31 DECEMBER 2024 2024 2023 FIXED ASSETS Intangible assets Tangible a8sety Investments 13 14 15 325,489 310,158 325.492 310,1Sg CURRENT ASSETS Slocks Debtors Cash at bank and in hand 16 17 25.120 239,796 153,797 23,171 248,395 226,926 418,713 {152,6001 498,492 1338,7251 CREDITORS: Amounts falling due within ono year 18 NET CURRENT A8SET811LIABILITIES) 266,113 159,767 TOTAL ASSETS LESS CURRENT LIA8ILITIE8 591,605 469.926 CREDITORS: Amounts falllng due after more than one year 19 11.33,4371 458,168 1115,9371 353,989 NET ASSET81(LIABILITIESI FUNDS Reslricled income lund8 Unreslricled Income funds 23 24 10,000 448.168 10.000 343,989 TOTAL FUNDS 458,168 353,989 Th88e fin8ncial statamanlg have been prepared Sn accordance wllh the provisions applicable to companSes subject to the small companies, regime. These flnanci slal ments were approved by the members of the committee and 8ulhori88d for issue on the .aiid are signed on their behalf by,. R 8ahu Trustee DireElor Company Registration Number: 6310215 The noles on pages 23 to 32 form part ol th859 linancial statem•nts. 19 Oocusign Envelope ID.. 5EB567BB_3EOA48C3-8EB4_8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY BALANCE SHEET 31 DECEMBER 2024 2024 2023 Note FIXED ASSETS Intangibla assets Tanglble a55els Investments 13 14 15 325,489 310.158 325,494 310,161 CURRENT ASSETS Debtors Cash at bank and in hand 17 279,750 126,251 266.038 213,563 406,001 (139.8901 479,601 1319.836) CREDITORS,. Arnounts falllng due wlthin on8 year 18 NET CURRENT ASSETSI{LIA8ILITIE3) 266,111 159,765 TOTAL ASSETS LESS CURRENT LIABILrriES S91,605 469,926 CREDITORS: Arnounts falling due after mor• than ono year 19 1133,4371 458,168 1115,9371 353,989 NET ASSETSIILIA8ILITIES> FUNDS Reslricled income fund9 Unreslricl•d income funds 23 24 10,000 448,168 10,000 343,989 TOTAL FUND8 458.168 353,989 Th8$9 financial $18tements have been prepar8d in accordance wilh the provisions applicable lo companie8 Subl￿t lo the small companie5, regirng, These flnJiic al sl ements were epproved by the members of the committ89 and aulhorised for issue on the .and are signed on thair behalf by.. R Bahu Trustee Director Company R8gi8tralion Number.. 6310215 Tho notes on pages 23 to 32 fonn part of Ihese financlal statemgnts. 20 Docusign Envelope10,' 5EB567BB-3EOA.48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CONSOLIDATED STATEMENT OF CASHFLOWS 31 DECEMBER 2024 2024 2023 Cash flowj from op•rallng actlvltles Net income 104,179 163,208) Adjuslrnents for.. Deprgcialion of tangible fixed assets Other intere51 r8ceiv3bl8 and similar inccfne Interest payable and similar Charges Accrugd oxpensesllincomel 6,829 12,077) 677 132,619) 951 12,1171 1,067 27,387 Changgs in.. Stock Trade and Dlher d•blors Trade and other creditors 11,947> 22.153 1149,5621 (5,149) 129,637) 99,641 Cash generated from operations (52,367) 28,935 Interest pald Interest received 1677) 2,077 11,0671 2,117 Net cash from operallng aclivilie8 150,967) 29,985 Cash flows from investing activities PurLliase of tangible ass8ls Purchase of investmen18 (22,1601 12} 11,8751 Nel cash used in investing activitie8 122,1821 11,8751 Cash flows from financing activiti08 Proceed5 from bcrrowings Nel cash (used inllfram fir)ancing acllvities Net Incr•aAelldeGr•a8el In ca•h and cash •qulval•nt• CaAh and cajh equlvalentg al b•glnnlng of year 173,1291 226,926 28,110 198.816 Cash and ca•h equlv•l•nts al •nd of y•ar 153,797 226,926 No¢•8 to th• Jtalement of cash flow8 can b• found In the notes to the flnan¢lal itatemenls page 30. The note5 on pago¥ Z3 10 32 form part of these financlal statements. 21 Docu$￿￿ Envelope ID.. 5EB567BB-3EDA48C3-8EB4-8BDE71138265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 2024 2023 Ca45h flow• from operating activities Net income 104,179 (63,208) Acljtjslments for.. Depreciation of18ngible Ixed 8s&el8 Other interest r8C8ivable and sirnilar income Interest payable and similar charges AGGru8d 8xpen688llincom&) 6,829 (2,077) 677 133,329) 951 12,1171 1.067 27.387 Changes in,. Trade and other debtor8 Trade and other creditors (160) 1142.672> 126,1821 98,197 Cash gqnoraled from operallons 166,5531 36.095 Iniere81 p8id Inter851 received 1677) 2.077 11,067) 2.117 Nel cash frorn operallng aclfvllles 165,153) 37.145 Cash flows from investing activltles Purchase (?1 tangible assets 122.1601 11,875) Nel cash u88d in investing aclivilies 122,1601 {1,875) Cash flow8 from flnanclng actlvltl•$ Proceeds from borrowings Nel cash Iu5ed Inllfrom financlng aclivitles Net Incroaiel{decrnai•l In cuh and caih •qulval•nt• C•$h and c•sh •qulvJlenls at b•glnnlnq of year 187,313) 213.563 35,270 178,293 Cash and cash 8qulval•nt• at end of year 126,250 213,563 Note8 to the statament of ca8h flows Con ￿ found In the not•$ lo the Ilnanelal •tat•m•nt• page 30. The notes on pages 23 to 32 forn) part of th¢¥e finJn¢lal $tatsm8nts. 22 Docusign Envelope ID.. 5EB567BB-3EOA46C34EB4_8BDE71138265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 ACCOUNTING POLICIES General InfO￿atIOn Tha charity 1$ a pnvate c(*Trpany limited by guarantee. registered in Ewland and Wales and 8 regisl8red charily in England and Wales. The add￿SS ol the registered Dflice is Lealhem House, 13 NapI￿r Court, Barton Lane. Abingdon, Oxon, OX14 3YT. Statement of ¢omplianGfr Th888 fin8ncial statements hav8 been prepared In compliance with FRS 102, The Fin8nci81 Reporting Standard appllcable In the UK and the Republic of Ireland,, the Stslement of Recommended Practice applicable lo charities p￿paring their 8ccounts in accordanc8 with the Financial Reporting Standard applicable the UK and Republlc of Ireland {FRS 1021 (Charities SORP IFRS 10211 effecllve January 2015, Update Bulletin 2 (October 20181 and the Charities Act 2011. Baslg of #ccountlng Th8 financial gtatement5 hav8 been prepared on th8 hislorlcal cost basis. as modlfled by the revaluation of ¢&rtair) financial asy&ls and liabilities and inveglm&nt propertlès meAsuf8d 8t fair value through income or expenditure. Golng concern Thp a(:Lounls havp IiÉ>en p￿par￿d on 8 gi)ing concern basis, as in Ihv opiniun c)1 Ilie Trustees, the cliarily will continue In operation lor the lure5eeablo lulure. Judgomfrntj and koy •ourc•A of •stimatlon uncertainty The prepar81ion of th& financial sl8lem8n18 requir8$ management lo make judgements, estlmales and assumptions that affect the amounts reported. Thesu eslimales and judgem8nls are continually revi8wed and are based on experlence and other f8Ctors. Including expectations ol future events that are beliovod lo be reasonoble under the cir¢umgtances. Basls of Consolldatioll The consolldaled accounts incorporate the results of Against Breast Cancer Llmlted and its sub8idiarie8 undertaking on a line by line basis. The consolidated ent6ty Is reterred to 88 'the Group., Incomlng ResourGos All incoming r¥50urces are included when the Charity Is legally entilled to the Income and the amount can be quantified with reasonable accuracy. Legaci88 are recognised when receipt is probable and entitlement Is e518bll3hed. No amounts are includ&d in the Financial Statements for Services don81ed by the volunteers. Gifts in kind arB included al the resale prfce or cos1 ID the donor, if more approprlale. Income relating to events taking plac8 after the yearend is deferred and included in the cr8dilors. The relevant costs associated with these events are also deferred and included in prepayments. Gift Ald reclaimed is accounted for when received. Allocation of expenditur• Staff costs are apportioned to fundraising, support. research and governance on a tlme spent basis. Depreoation incurred on fSxed assets 15 for the charity's own tJ8e and Allocatad lo costs of generating voluntsry Incom8. 23 Doojsign Envelope10.' 5EB567B8.3EOA_48C3.8EW8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 Amortlgatlon Amortlsalion is calculated so as to write off th8 C05t of an as5eC 1855 ils estimated r88idual valuo, ovpr the Usefvl 8conornic life of that as¥et as follow5.' Palent8- 25% on cost Fixed a88ats All fixed ass8ts aTe initially Tecorded at Cost. Dopreciation The fr8ehold property Is not deP￿CIated 85. in th8 oplnlon of the Tru8t¥eg, tho building elernenl of the valu8 ha8 not diminishad in value since acquisllion. 08pr8cialion is calGulAled 80 a8 to write off the cost of an 838el, less Ils 88llm8led r8sidu81 value, over the useful economic life of that a5sel as follows.. EquiF)menl - 25% Slralghl Line Stock• Stocks are valued al the lower of cost and nel reallsable value, aftor m8king due allowance lor obsolete and low rnoving ilem8. Dabtor• Trade and othaT debtors are recognised al the Settlement arnounl due after any Ir8de discount offered, Prepayment5 are valuèd ot the amount pr6paid net of 8ny trade discounlg due. C•Bh at bank and in hjnd Cash at bank end cash in hand includes cash and short tenn highly liquid inv8slm8nts wllh 8 Short m8lurlty of thr88 months or less from the dale of acquisition or opening of the deposit or simllar account. Credltorfj and provision• Creditors and provision are recognlsed where th8 charity has a pre58nl obllgation resullino from a pa81 ev8nt that will probably result in the transfer of funds to 8 thlrd party and the amount due lo sellle the obligation can be measured or eslimal8d r&li8bly, Cr8dilor8 and provisions are norfflolly recognised al their settlement amount after allowlng for any trade discounts due. Pen¥lons The Group operates a defined contribution pension 8cheme. Contributions ar8 charged in the profit and loss account as they b8com8 payable in accordance with rules of the scheme. Op•ratlng Lowses Rentals payable under operating leases are charg*J in the profil 8nd IOBB account on a slTaighl lin8 basis over the lease term. Inve•tment pollcy In the Charity balance sheet the inv85trnent in the tradlng subsldiary is slat8d al rost. 24- Docuslgn Envelope ID.. 5E85676B-3EOA48C3_8EB4-88DE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 VOLUNTARY INCOME Group 2024 Charity 2024 Group 2023 Charlly 2023 Donations Donations, grants and gifts Trust income Sporting events Glft Aid redaimed Donall¢M from subsidi8ry Legacies Legacies 267,177 4,500 327.844 45.889 267.177 4.500 327.844 45.889 83,125 410,014 13.000 279,951 40,261 410.014 13,000 279,951 40,261 189,408 245,529 245,529 98,612 98,612 890.939 974,064 841,838 1,031,246 2024 income includes reslricleo 9r8nts totalling £35,628. 2023 income Includ8s restrlcted donations tolalling £150,758. Donatlon Incoma Include8 £NII12023.' £Nil) In re$peGt of gifts in kind donated to the Charily, INCOMING RESOURCE8 FROM ACTIVITIES FOR GENERATING FUNDS Group 2024 Charlty 2024 GfOUP 2023 Charity 2023 Recycling in(om• Trading incorne of subsidiary 3.849 181.691 3,849 805 265,293 805 185,540 3,849 266,098 805 All Income is unrestricted for both year8. OTHER INVESTMENT INCOME Group 2024 Charity 2024 Group 2023 Charity 2023 Bank Interest receivable 2,077 2,077 2,117 2,117 All income is unrestricted for both yaars. OTHER INCOME Group 2024 Charlty 2024 Group 2023 Charily 2023 Man8g8ment charge from subsidiary All income Is unrastricled for both years. 80,000 65.000 25 Doojsryn Envelope ID.. 5EB567BB-3EQA-48C3-8EW8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 COSTS OF GENERATING VOLUNTARY INCOME Group 2024 Ch•rlty 2024 Group 2023 Charity 2Q23 Donations Event Fundraising Trading costs of subsldiary Support costs 171,485 258.087 14,295 217,B04 171,485 258.087 151,769 227,158 7,765 224,078 151,789 227,158 217,804 224.078 661,871 847,376 610,770 603,005 All expenditure 15 unre8lricted for both years. COSTS OF CHARITABLE ACTIVITIES BY FUND TYPE Group 2024 Charlty 2024 Group 2023 Ch8rity 2023 Research 234,227 234,227 Th8 ro88arch axpendilure lor the year contains a credll r8P8ymenl 01 £196,884 in re8p8cI of an underspend on the 5 year Di$¢over proj8cl. The Trug18&5 intorvJ lo relnvest these fvnds in the ongoing research of thè Charity. 545.043 545.043 Grants of £nll were paid lo individuals in tha year Ic support r8ya8r¢h12023: £nil). 2024 experidilure includ¥s r¥slrir.l¥d c051¥ lol¢illing £150,758, 2023 expenditure includes resth'cled cosis 101811ing £187.963. CO8T8 OF CHARITABLE ACTIVITIES BY ACTIVITY TYPE Voluntary Fvndralslng ev•nt Fundrai•ing Support Costs Total 2024 Tol81 2023 Wage5 & 3alari85 Employers Nl Staff Pension Staff r8cruilmenl & Irainlng Rates & water Light & heat Insurance Telephone 231,078 1U,178 10.831 4,739 Z,009 544 1,539 1,382 133,149 13,188 6,598 4,739 5,021 1,361 3,848 345 364,227 29,366 17,429 9,478 10,043 2,722 7,696 3,454 371,957 30.556 17,884 13,990 7,652 1,720 6,496 5,474 3,013 817 2,309 1,727 L Illjl Depreciation Stationery Publicity Event managemenl Consultant Oalabase costs Travel Property Tepair8 & maintenance Agency fees online giving Miscellaneous Office equipment & h8rdw8r8 Pogtage 3,414 4,728 1,743 74,081 14,405 2,732 3,783 3,236 31,749 14,405 683 946 6,629 9,457 4,979 105,830 28,610 31,059 475 337 951 12,440 13,524 76,218 31,059 47 30,858 570 1,139 238 337 190 328 1,070 5.575 141 713 4,460 469 3.566 11,150 57 3.576 7.963 1,783 Charity expenditure 113.785 329.709 203.882 647,376 603.005 Tratling purchases 14.295 14,295 7,765 Group expenditure 128.080 329.709 203,882 661,671 610.770 26 DOcus￿n Envelope ID.. SE8567B&3EOA48C&8EB44BDE71138265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 2024 expenditure includes restricted c4)sts tot8111ng £35,628. 2023 expenditure includes r681ricted cos18 lotalling £150,758. OTHER COSTS Group 2024 Charity 2024 Group 2023 Charity 2023 Employern NIC Accountancy f88S Audit lees Leg81 fees Interest payable CorporBlion Tax charge for year Other flnancial c0818 (5.000 (5,000) (5,0001 (5,0001 13.43S 11.168 a,592 10,050 11,168 8,592 13.628 1,024 6,183 11.053 1,024 6.183 1,563 677 1,613 1,068 29,758 25,487 17,448 14,328 All expendllure is unrestricted fof bolh y•arg. 10. NEf INCOMING RESOURCES FOR THE YEAR This is $18ted aller charging.. Group 2024 2023 Staff pension contributions Depr8ciakn'on Auditors, remuner81ion: audlt of the finanGial statements 19,052 6,829 17,864 951 13,435 13,628 Charlty 2024 2023 Staff pension contributions Depreciation ALbdilors' remuner8ts0n'. audit of the finanGial sletements 19,052 8.829 17.884 951 10,050 11,053 11. STAFF COSTS AND EMOLUMENTS Total staff costs were as follows: 2024 2023 Wagos and salaries SoGial SBcurily costs Other pension costs Redundancy and termination payments 406,718 33,975 19.052 371,957 30.556 17,864 459,745 420,377 Particulars of employees: Th8 average number of employee5 during the year, Galculated on Ihe b85is of full-lime equivalents, was as follows.. 2024 No 2023 No Number of research staff Number of fundralsing staff Nurnber of 5UPPOrt staff 27 Docuslgn Envelope ID.. 5EB5678B.3EOA48C3-8EB4.8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 The number of highly paid employeas was as follows:. 2024 No 2023 No £60,000- £65,000 £65,000- £70,000 No Trustees were remunerated during the year under roview12023- Nil) 12. TAXATION- GROUP In respect ol the year 2024 2023 Taxallon based on results for the year 13. INTANG18LE FIXED ASSETS- GROUP AND CHARITY Patont COST At 1 JJnu¥ry 2024 and 31 D•c•mb•r 2024 2,782 AMORTISATION At 1 January 2024 31 December 2024 2,761 NET 800KVALUE At 31 Docember 2024 At 31 D8c8mber 2023 14. TANG18LE FIXED ASSETS- GROUP AND CHARITY Freehold property Equlprnent Total COST At 1 January 2024 Additions 307,782 40,884 22,160 348.666 22,160 At 31 Dec•mb•r 2024 307.782 63.044 370,826 DEPRECIATION At 1 Januory 2024 Charge for the year At 31 Dqc•mbgr 2024 38,508 6,829 38,5Q8 6,829 45,337 45,337 NET 800K VALUE At 31 December 2024 307,782 17,707 325,489 At 31 December 2023 307,782 2.376 310,158 28 Doujsign Envelope ID.. 5E8567BB-3EOA48C3_8EB4_8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 15. INVESTMENT8- GROUP Group COST At 1 January 2024 Additions At 31 December 2024 NET BOOK VALUE At 1 January 2024 Additions At 31 Decernber 2024 Durlng the yeor the Group acquired £2 in unllsled sh8r&8 Charlty COST Al 1 January 2024 Additions At 31 December 2024 NET 800K VALUE AI 1 JAnuHry 2024 Addilinns Al 31 December 2024 Cuunlry of incorporali(?n Holding Proportion ol voting righls and shares held Subsidiary undortaklng Against Breast Cancer Trading Limited 8ub8idlary und•rtaklng EnG18nd Ordinary share 100% Against Brea51 Cancer Holdings Limilad England Ordinary share 100% The Investments represent the cost of IOOOA of the share c8pltal of Agalnst 8reasl Cancer Trading Limiled and Against Brea51 Cencer Holdlngs Limiled, companies Incorporated In England and Wale9, 16. STOCKS 2024 2023 Stock 25,120 23,171 17. DEBTORS Group 2024 Charlty 2024 Group 2023 Charity 2023 Trade debtors Amounts owed by group undertaking5 Other debtor5 Prepayments 22,254 102 62.107 48,254 1,403 64,599 217.542 217,542 200.141 200,036 239,796 Z79,751 248,395 266,038 29 Doojslgn Envelope ID.. 5EB5678B.3EDA_48C3.8EB4.8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 18. CREDITORS: Amounts falllng due within one year Group 2024 Charlty 2024 Group 2023 Charity 2023 8ank loan5 and overdraft Trade creditors Amounts owed lo group undertaking5 Corporation T8X Taxation and social s8curily Olhgr Gredilors Accrua18 16,703 16,703 154,961 151,870 18.7n 9,270 22,576 7,497 153,691 9,278 7,497 151,191 117.124 113,916 152,599 139,890 338,725 319,836 19. CREDITORS.. Amounts falllng duo aftor more than one yoar Group 2024 Charlty 2024 Group 2023 Charity 2023 Acc*uals 133,437 133,437 11 S,937 115,937 133,437 133,437 115,937 115,937 20. Analysls of cash and cash equlvalents Group 2024 Charity 2024 Group 2023 Ch8rily 2023 Cash In Hand 21. Analysi8 of change8 In net debt (Con8011dated cash flow Jtatement) Balance at I January 2024 Ca¥h Flows Bal•nc• at 31 D•¢emb•r 2024 Cash 8nd Cash equivalents Loans due within 1 year Loans after 1 year 226,926 173,1291 153,797 Total 226,926 {73,1291 153.797 22. Analysls of changes In net debt (Charity cash flow statement) BalancB al 1 JanuJry 2024 Cash Flow3 Balance at 31 December 2024 Cash and Cash equivalents Loan5 due within 1 year Loans arter 1 yB8r 213,563 187,3131 126,250 Total 213,563 la7,3131 126,250 30 Docusign Envelope ID.. 5EB587BB-3EOA48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 23. RESTRICTED INCOME FUNDS Blllance at 1 January 2024 Balance at Expenditure 31 DeG 2024 Income Stewart¥ Law Foundation The Medical Research Council 10,000 10,000 35,628 135,6281 135,6281 10,000 35,628 10,OQNJ Stewarts Law Foundatlon Stew8rts Law FoLJndallon granted Against Breast Cancer£lO,000 lo fully ¢alalogue the blood & urine samples collec18d during our 5 year clinical trial - DielComLyf. The colleclion is the largest r88ource of ils kind in the UK and look approximately 16 years lo collect The Medical Research Councll The hAedlcal Rese8rch Cauncil repealad Ih8ir funding support og8in in 2024 to h81p sustain early-car8er researchers curr8nlly supportBd by medical research charilles. This SUPPDrt, from the D¥partrn8nl of 8usiness. Energy 8nd Industrial Strategy IBEISI and the Department of Health and Social Care IDHSCI, was In recognition of the 10ss8s the research 80Ctoi suffered as a result of Covid-19. The resulting 'M8dical R85earEh Charitles Early Career Researchers Support Fund. 8iffl8d to support and susiain charity-funded fgsearchers early on In their career. This induded PhD students and Ihosa with less than 10 years research experience posl.PhD. As 8 member of the AMRC, Again$1 Breast CanGgr were eligible lo once again app for this support and could nomina18 up lo 10 wsearohers that we fund8d during tho 202312024 financial year. Thp succcssful aiipliLaliun fur this significant granl TiJi)ding was vilal lo the finances of Aqainsl Breasl Cancer lid WAS much appreciated by the Iruslees. 24. UNRESTRICTED INCOME FUNDS Balan¢0 at 1 January 2024 Incornin re•ourco5 Outgoing 8alancg at 31 re•ourcg4 December 2024 Grcup General Funds 343,989 1,042.929 1974,376) 1920,183) 448,168 448,168 Charity Ganeral Fund5 343,989 1,024,362 25. ANALYSIS OF NET ASSETS BETWEEN FUNDS Net current agset>l Illabllltles) Long Torm Llabilltles Intangl￿e flxed aJsgt8 Tanglbl flxed assets Total Group UnrestriGtod Income Fund• 2024 325,492 266,113 (133,437) 458.168 Charlty Unre¥Jtrlcted Income Fund* 2024 325.494 266.111 (133,437) 458,168 Group Restrictgd Incom8 Funds 2024 10,000 10,000 Charity R?8trlct•d Income Funds 2024 10,000 10,000 31 Doojslgn Envelope 10.. 5E8567BB-3EOA-48C3-8EB4-8BDE7113B265 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHARITY STATEMENT OF CASHFLOWS 31 DECEMBER 2024 N•t ¢urrant as8•tsl Illabllltle*} Lonq Temi Liabilities Inlangible fixed as¥ot8 Tanglble Ilx•d a#*èt* Total Group Unre•trlctod Incomo Funds 2023 310,158 159,768 (115,937) 353,989 Charlty Unrestricted Incom• Fund• 2023 310,160 159,766 (115,937) 353,989 Group Rostrl¢t8d In¢ome Funds 2023 i 0,000 1a,000 Charlty R••trlct•d Incom• Fundi 2023 10,000 10,000 26. RELATED PARTY TRANSACTIONS Al 318t December 2024 the Charity wa8 nwpd £62,107 (2023.. £64,599> by 115 1 OOQA owned subsidiary. Agairi%l Breast C8nG8r Trading Liilliled as a result of trade charges, and charity income rec￿1v&d by the subsidiary less expenditure incurred on the subsidbary's behalf. At 3181 D8cember 2024 the Ch8dty owed £1 (2023.. £nil) lo ils 100% owned subsldlary, Ag8in81 Breast Canc8r Trading Limited as a result of trada charg88. and charlty Income received by the subsidiary less expenditure incurred on the 8ub8idiary'8 behalf. 27. COMPANY LIMITED BY GUARANTEE The Company Is Ilmited by guarantee With no issued share capital. There 15 no ultimate controlling party. 28. CAPITAL COMMITMENTS At 31 December 2024 th8 Company had tho authonsed capital commllmenls lotalllng £NII (2023.. £Nil). 29. LEASING COMMITMENTS Mlnlmum lea80 payments under nonvcancellable operatlng lea808 fall due as follows:. 2024 2023 Wilhln one year etween one and five years Over 5 years 2,385 2,385 32